BioCryst Pharmaceuticals, Inc. (BCRX) Posts Q3 Loss of $0.32, Sales Miss Expectations
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.62 -1.82%
EPS Growth %: -43.8%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -43.8%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q3 EPS of ($0.32), $0.06 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $5.25 million versus the consensus estimate of $6.84 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Thor Industries (THO) Misses Q4 EPS by 13c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
